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Original Article
The STAT5A-Mediated Induction of Pyruvate
Dehydrogenase Kinase 4 Expression by Prolactin or
Growth Hormone in Adipocytes
Ursula A. White, Ann A. Coulter, Tiffany K. Miles, and Jacqueline M. Stephens
The purpose of this study was to determine whether pyru-
vate dehydrogenase kinase (PDK)4 was expressed in adi-
pocytes and whether PDK4 expression was hormonally
regulated in fat cells. Both Northern blot and Western blot
analyses were conducted on samples isolated from 3T3-L1
adipocytes after various treatments with prolactin (PRL),
growth hormone (GH), and/or insulin. Transfection of
PDK4 promoter reporter constructs was performed. In
addition, glucose uptake measurements were conducted.
Our studies demonstrate that PRL and porcine GH can
induce the expression of PDK4 in 3T3-L1 adipocytes. Our
studies also show that insulin pretreatment can attenuate
the ability of these hormones to induce PDK4 mRNA ex-
pression. In addition, we identified a hormone-responsive
region in the murine PDK4 promoter and characterized a
STAT5 binding site in this region that mediates the PRL
(sheep) and GH (porcine) induction in PDK4 expression in
3T3-L1 adipocytes. PDK4 is a STAT5A target gene. PRL is a
potent inducer of PDK4 protein levels, results in an inhi-
bition of insulin-stimulated glucose transport in fat cells,
and likely contributes to PRL-induced insulin resistance.
Diabetes 56:1623–1629, 2007
I
t is well known that growth hormone (GH) and
prolactin (PRL) induce signaling via the JAK-STAT
pathway. In particular, STAT5 proteins are potently
activated by these hormones (rev. in 1). GH is
known to have profound effects on lipid metabolism (rev.
in 2). The effects of PRL have been well characterized in
mammary tissues, yet there is also evidence demonstrat-
ing that this hormone can affect adipose tissue in mice and
humans (3,4). Yet, few molecular targets for the STAT5-
mediated actions of GH and PRL on adipocytes have been
identified. Although multiple lines of recent evidence
suggest that STAT5 proteins can modulate adipocyte func-
tion (5–11), very few studies have identified direct STAT5
target genes in adipocytes. We recently observed that the
GH and PRL inhibition of fatty acid synthase (FAS)
transcription was mediated by a STAT5A binding site in
the rat FAS promoter (12). Hence, our current efforts have
been to identify other genes associated with glucose or
lipid metabolism that are directly modulated by STAT5
proteins in adipocytes. In this study, we present data
demonstrating that pyruvate dehydrogenase kinase
(PDK)4 is a STAT5A target gene.
PDK is a family of kinases that negatively regulate the
activity of the pyruvate dehydrogenase complex (PDC)
(rev. in 13). There are four tissue-specific isoforms of PDK,
PDK1–4, that have been identified in mammals, and each
has different patterns of gene expression (14–16). The
specificity in distribution, expression, and activity of each
PDK isoform contributes to the long-term regulation of
PDC in a given tissue and thus, in part, regulates glucose
metabolism. There are several conditions that result in the
short-term regulation of PDC activity (17–19). The long-
term regulation of PDK that occurs in starvation (18,20)
and diabetes involves an increase in the amount of PDK
protein, which results in stable increases in PDK activity
(21). An induction of PDK4 leads to decreased glucose
oxidation, which results in hyperglycemia. PDK4 expres-
sion has also been shown to be induced by high-fat feeding
in skeletal muscle (22). A study in nondiabetic Pima
Indians, a group prevalently stricken with obesity and type
2 diabetes, has demonstrated that increased levels of
muscle PDK4 expression positively correlate with in-
creased fasting plasma levels of insulin and negatively
correlate with insulin-mediated glucose uptake (23). It has
also been documented that insulin has the ability to
suppress PDK4 expression in skeletal muscle and hepa-
toma cells (23–25). Increased insulin sensitivity in post-
obese patients has also been shown to be associated with
decreased PDK4 expression (26).
In our present study, we examined the modulation of
PDK4 in adipose tissue. Our studies clearly demonstrate
that PRL and GH can induce the expression of PDK4 in
3T3-L1 adipocytes. Our studies also show that insulin
pretreatment has the ability to attenuate the ability of
these hormones to induce PDK4 expression. In addition,
we identified a hormone-sensitive region in the murine
PDK4 promoter and characterized a STAT5 binding site in
this region, which mediates the hormonal effects on PDK4
expression. Also, when PDK4 protein was induced, we
observed an inhibition in insulin-stimulated glucose up-
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take. In summary, our studies indicate that PDK4 can be
induced in adipocytes and may play a role in insulin
resistance.
RESEARCH DESIGN AND METHODS
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Invitro-
gen. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals, and
calf serum was purchased from Biosource. PDK4 antibodies were purchased
from Abgent. Porcine and human GH and sheep PRL were purchased from
Sigma. STAT5A antibodies were purchased from Santa Cruz. An antibody
directed against active mitogen-activated protein kinase (MAPK) was pur-
chased from Promega. [-32P]dCTP was purchased from Perkin-Elmer and
Amersham Biosciences. Deoxynucleotide thymine triphosphate, dATP, and
dGTP were purchased from Amersham Biosciences. Oligonucleotides were
purchased from Integrated DNA Technologies. DNAse polymerase I large
(Klenow) fragment was purchased from Promega.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown to 2 days
after confluence in DMEM containing 10% bovine serum. Medium was
changed every 48 h. Cells were induced to differentiate by changing the
medium to DMEM containing 10% FBS, 0.5 mmol/l 3-isobutyl-methylxanthine,
1 mol/l dexamethasone, and 1.7 mol/l insulin (MDI). After 48 h, this medium
was replaced with DMEM supplemented with 10% FBS, and the cells were
maintained in this medium until used for experimentation. For serum depri-
vation, cells that were between 7 and 10 days after MDI were placed in DMEM
supplemented with 0.15% fatty acid free and growth factor–depleted BSA for
16–20 h.
Preparation of whole-cell extracts. Cell monolayers were rinsed with PBS
and then harvested in a nondenaturing buffer containing 10 mmol/l Tris (pH
7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-100, 0.5%
Nonidet P-40, 1 mol/l phenylmethylsulfonyl fluoride, 1 mol/l pepstatin, 50
trypsin inhibitory mU aprotinin, 10 mol/l leupeptin, and 2 mmol/l sodium
vanadate. Samples were extracted for 30 min on ice and centrifuged at 15,000
rpm at 4°C for 15 min. Supernatants containing whole-cell extracts were
analyzed for protein content by BCA analysis (Pierce) according to the
manufacturer’s instructions.
RNA analysis. Total RNA was isolated from cell monolayers with Trizol
(Invitrogen) according to manufacturer’s instructions with minor modifica-
tions. For Northern blot analysis, 15 g total RNA was denatured in form-
amide and electrophoresed through a formaldehyde/agarose gel. The RNA
was transferred to Zeta Probe-GT (Bio-Rad) in a buffer containing 75 mmol/l
sodium citrate tribasic, 10 mmol/l NaOH, and 750 mmol/l NaCl. Probes were
labeled by random priming using Klenow fragment and [-32P]dCTP.
Plasmid constructs. A 973-nucleotide segment of the PDK4 promoter (949
to 24) was cloned from murine Sv/129 liver genomic DNA using the following
PCR primers: forward, ATGACCCGCTAGCATGTTTC; reverse, GGTGAA
GGGTTGACACTTGG. Nucleotides were added to the 5 ends of each primer
so that the forward primer could be digested by KpnI and the reverse primer
by SacI for directional ligation into the multiple cloning site of pGL3-basic
KpnI/SacI to create pGL3-PDK4pro. The STAT element in pGL3-PDK4pro
(TTCTTGGAA) was mutated to TTTATGGAA using the QuickChange II Site
Directed Mutagenesis kit (Stratagene) with the following primer and its
antisense, CACGCTCCGCGGTGAGATTTATGGAAACAGTTTCTGGCTAG, to
create pGL3-PDK4mut. Plasmids were sequenced for verification of wild-type
and mutagenic nucleotide sequences using Big Dye Terminator Extension
Reactions (ABI).
Transfections and luciferase reporter assays. 3T3-L1 adipocytes in six-
well plates were transfected on day 3 of differentiation after addition of
DMEM containing 10% FBS and 425 nmol/l insulin. Either 2.5 g pGL3-
PDK4pro or 2.5 g pGL3-PDK4mut was cotransfected with 250 ng pRL-CMV/
renilla vector to control for transfection efficiency in each well using Fugene
6 (Roche). After 32 h, cells were serum deprived overnight in DMEM with
0.15% BSA, untreated or treated with PRL for 2 or 4 h, and harvested. Cell
lysates were assayed for firefly and renilla luciferase using the Dual Luciferase
Reporter System (Promega). Relative light units were calculated by dividing
firefly luciferase activity values by renilla luciferase.
Preparation of nuclear and cytosolic extracts. Cell monolayers were
rinsed with PBS and then harvested in a nuclear homogenization buffer and
centrifuged to isolate cytosolic and nuclear extracts as previously described
(27).
Gel electrophoresis and immunoblotting. Proteins were separated in 7.5%
polyacrylamide (National Diagnostics) gels containing SDS according to
Laemmli (28) and transferred to nitrocellulose (Bio-Rad) in 25 mmol/l Tris, 192
mmol/l glycine, and 20% methanol. After transfer, the membrane was blocked
in 4% milk overnight at 4°C. Results were visualized with horseradish
peroxidase–conjugated secondary antibodies (Jackson ImmunoResearch Lab-
oratories) and enhanced chemiluminescence (Pierce).
Electrophoretic mobility shift analysis. Double-stranded oligonucleotides
were end-labeled with [-32P]dCTP using Klenow. Binding reactions were
performed with nuclear extracts, according to Ritzenthaler et al. (29). The
sequence of the oligonucleotide used was 5-GTGAGATTCTTGGAAACAGTT-
3. Protein-DNA complexes were resolved and visualized as previously
described (12). For supershift analysis, nuclear extracts were preincubated
with 4 g antibody for 1 h at room temperature.
Determination of [3H] 2-deoxyglucose uptake. The assay of [3H] 2-deoxy-
glucose uptake was performed as previously described (30). Before the assay,
fully differentiated 3T3-L1 adipocytes were serum deprived for 4 h. Uptake
measurements were performed in triplicate under conditions where hexose
uptake was linear. The results were corrected for nonspecific uptake, and
absorption was determined by [3H] 2-deoxyglucose uptake in the presence of
5 mol/l cytochalasin B. Nonspecific uptake and absorption was always 10%
of the total uptake.
RESULTS
Several previous studies have demonstrated an induction
of PDK4 in skeletal muscle (22,24); but, the induction of
PDK4 expression in adipocytes has not been previously
examined. In the course of studying activators of STAT5A,
we observed an induction of PDK4 mRNA by PRL. Total
RNA was isolated from fully differentiated 3T3-L1 adipo-
cytes after treatment with PRL for the times indicated.
PRL is known to induce the expression of suppressors of
cytokine signaling (SOCS)-3. As shown in Fig. 1A, the
FIG. 1. PRL induces PDK4 expression in a time- and dose-dependent
manner in 3T3-L1 adipocytes. A: Total RNA was isolated from serum-
deprived 3T3-L1 adipocytes after 20 nmol/l (480 ng/ml) PRL treatment
for the times indicated. Untreated cells (0) were also harvested at the
start of the time course. Fifteen micrograms total RNA was electro-
phoresed, transferred to nylon, and subjected to Northern blot analysis
with radiolabeled probes for PDK4, PDK2, and SOCS-3. Ethidium
bromide staining of 28S and 18S RNA is also included. This is a
representative experiment independently performed four times. B:
Total RNA was isolated from serum-deprived 3T3-L1 adipocytes after a
2-h PRL treatment with the doses indicated. Untreated cells (0) were
also harvested at the start of the experiment. Fifteen micrograms total
RNA was subjected to Northern blot analysis. This is a representative
experiment independently performed three times.
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efficacy of PRL was demonstrated via the induction of
SOCS-3, which occurred after a 30-min treatment. In
addition, PRL induced the expression of PDK4 mRNA, as
evidenced by the robust expression at 2 h. Between 2 and
6 h, the induced PDK4 mRNA was apparent. In addition,
PRL did not have any substantial effect on the expression
of PDK2. Ethidium bromide staining of 28S and 18S RNA
was included as a loading control. To further examine the
modulation of PDK4 by PRL, fully differentiated 3T3-L1
adipocytes were treated with various doses of PRL for 2 h.
As shown in Fig. 1B, PRL treatment resulted in a dose-
dependent increase in PDK4 mRNA. Physiological levels
of PRL, 0.5 nmol/l (12 ng/ml), were capable of inducing
PDK4 mRNA. An analysis of -actin mRNA levels is
included as a loading control.
Because PRL is a potent STAT5 activator, we also
examined the effect of GH, another hormone known to
activate STAT5 in adipocytes. As shown in Fig. 2A, a 2-h
treatment with sheep PRL or porcine GH resulted in an
induction of PDK4 mRNA. Yet, human GH did not have
any effect on PDK4. Further analysis revealed that PRL
and pig GH resulted in an equivalent level of STAT5
phosphorylation (Fig. 2B), but human GH was also
capable of activating STAT5 to a lesser extent. Interest-
ingly, all of the hormones resulted in equivalent levels of
extracellular signal–related kinase (ERK) 1 and 2 (active
MAPK) activation.
To further examine the specificity of the induction of
PDK4, we examined the effects of several STAT1 and
STAT3 activators. We have previously shown that these
cytokines are potent activators of STAT1 or STAT3 or both
of these STATs in 3T3-L1 adipocytes but do not activate
STAT5 proteins (27,31). Total RNA was isolated from
serum-deprived 3T3-L1 adipocytes after a 2-h treatment
with ciliary neurotrophic factor, cardiotrophin-1, leukemia
inhibitory factor, interferon , or PRL. As shown in Fig. 3,
we observed that PRL, but not any of the other cytokines,
induced PDK4 expression. -Actin is included as a loading
control. The efficacy of the cytokines was confirmed by
examining STAT activation (data not shown).
Because previous studies suggest that insulin has the
ability to suppress PDK4 expression in other tissues
(23–25), we examined the PRL- and GH-mediated induc-
tion of PDK4 mRNA after an insulin pretreatment in
adipose tissue. Fully differentiated 3T3-L1 adipocytes were
treated with porcine GH or PRL for 2 h in the presence or
absence of a 20-min insulin pretreatment. The robust
activation of PDK4 mRNA after the treatment with either
PRL or GH was evident with no insulin preincubation, but
the induction of PDK4 mRNA was substantially attenuated
by the insulin pretreatment (Fig. 4).
Because PRL and GH are potent activators of STAT5, we
searched the murine PDK4 promoter for STAT binding
motifs in the promoter region 2.5 kb upstream of the
transcription start sites. Typically, STAT proteins bind a
core palindromic sequence, TTC NNN GAA, and selective
variation can occur in particular nucleotide positions (32).
One consensus STAT binding motif was identified at 389
in the PDK4 promoter. An oligonucleotide probe contain-
ing 9 bp of the core STAT motif with 6 bp of flanking
sequence on either end was incubated with cytoplasmic or
nuclear extracts from PRL-treated 3T3-L1 adipocytes. To
evaluate this potential STAT5 binding site, we performed
electrophoretic mobility shift assays (EMSAs). As shown
in Fig. 5A, we observed PRL-induced binding when the
labeled probe was incubated with nuclear extracts from
PRL-treated adipocytes. Specific binding to the probe was
also confirmed by results demonstrating that cytosolic
proteins did not bind to this site, and preincubation with
unlabeled probe decreased binding intensity (Fig. 5A, last
lane). Preincubation of nuclear extracts with specific
antibodies to individual STAT proteins in a supershift
EMSA indicated that STAT5A was present in the binding
complex induced by PRL (Fig. 4B). In addition, STAT1 and
STAT3 did not participate in binding to the STAT element
in the PDK4 promoter. Our data clearly demonstrate that
the 389 to 378 region of the murine PDK4 promoter
binds nuclear PRL-activated STAT5A proteins in vitro. To
determine whether this region of the PDK4 promoter
contributed to the regulation of PDK4 by STAT5 activators
in living cells, we performed site-specific mutagenesis to
FIG. 2. Both PRL and porcine GH induce PDK4 expression in 3T3-L1
adipocytes. A: Total RNA was isolated from serum-deprived 3T3-L1
adipocytes after a 2-h treatment with 0.5 nmol/l PRL (P), human GH
(h), or porcine GH (p). Untreated cells (CTL) were also harvested at
the start of the experiment. Fifteen micrograms total RNA was elec-
trophoresed, transferred to nylon, and subjected to Northern blot
analysis with radiolabeled probes for PDK4 and -actin. Ethidium
bromide staining of 28S and 18S RNA (gel photo) is also shown. This is
a representative experiment independently performed four times. B:
From the same group of cells, whole-cell extracts were isolated after a
15-min treatment with the same doses of the hormone listed above.
Twenty-five micrograms protein from each sample was subjected to
SDS-PAGE and then was transferred to nitrocellulose for immunoblot
analysis. This is a representative experiment independently performed
four times.
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alter 2 bp within the murine PDK4 promoter/luciferase
construct. We have shown that this mutation abolished
binding of PRL-induced proteins to this site (data not
shown). Transfection of the wild-type and mutant con-
structs into 3T3-L1 cells revealed that the basal level of
luciferase activity was not significantly affected by muta-
tion of the STAT5A site that we identified in the PDK4
promoter (Fig. 6). In addition, a two- to fourfold increase
in luciferase activity was observed after a 2-h PRL or GH
(porcine) treatment and measurement of the wild-type
construct. In addition, the construct containing the mu-
tated STAT5 site was unresponsive to induction by GH or
PRL. Thus, these data clearly indicate that the 389 to
378 site of the PDK4 promoter is sensitive to GH and
PRL, and these data also suggest that this site confers the
positive regulation of PDK4 by GH- and PRL-activated
STAT5A protein complexes.
The expression and modulation of PDK4 in skeletal
muscle is well documented, yet, the induction of PDK4 in
adipocytes has not been previously observed. Because our
studies indicate that PRL increased PDK4 mRNA levels,
we hypothesized that PDK4 protein levels might be in-
creased after PRL treatment. Hence, we exposed fully
differentiated serum-deprived 3T3-L1 adipocytes to PRL
and isolated whole-cell extracts to examine PDK4 expres-
sion. Chronic treatments (22 h or more) did not result in
any substantial changes in PDK4 protein levels (data not
shown). Because the effects of STATs on gene expression
are usually transient, we examined the ability of shorter
PRL treatments to modulate PDK4 expression. As shown
in Fig. 7, we observed a significant induction of PDK4
protein levels after a 6- and 8-h treatment with PRL. After
24 h, this induction was not substantial. We did observe
some fluctuation in the time in which PRL induced levels
of PDK4 protein. In some experiments, we observed a
substantial induction at 4 h, whereas in most experiments,
FIG. 3. STAT1 and STAT3 activators do not induce PDK4 expression in
3T3-L1 adipocytes. Total RNA was isolated from serum-deprived
3T3-L1 adipocytes after 2 nmol/l ciliary neurotrophic factor (CNTF),
0.2 nmol/l cardiotrophin-1 (CT-1), 0.5 nmol/l leukemia inhibitory factor
(LIF), 100 units/ml interferon  (IFN), or 0.5 nmol/l PRL treatment.
Untreated cells (CTL) were also harvested at the start of the experi-
ment. Fifteen micrograms total RNA was subjected to Northern blot
analysis. This is a representative experiment independently performed
two times.
FIG. 4. The induction of PDK4 by PRL or GH is attenuated by insulin
pretreatment in 3T3-L1 adipocytes. Total RNA was isolated from
serum-deprived 3T3-L1 adipocytes after 2-h treatments with 0.5 nmol/l
porcine GH or 0.5 nmol/l PRL in the presence or absence of a 20-min 50
nmol/l insulin pretreatment. Fifteen micrograms total RNA was sub-
jected to Northern blot analysis. This is a representative experiment
independently performed three times.
FIG. 5. PRL induces binding to a potential STAT site at 389 to 378
of the mouse PDK4 promoter in vitro. A: Cytosolic and nuclear extracts
were prepared from differentiated serum-deprived 3T3-L1 adipocytes
that were untreated or treated with PRL for 15 min. For each sample,
10 g protein was incubated with 50,000 cpm/ml 389 to 378 32P-
labeled probe of the murine PDK4 promoter. The protein-DNA com-
plexes were resolved by EMSA. For cold competition, nuclear extracts
were preincubated with an excess of the indicated unlabeled oligonu-
cleotides (10 mol/l). The PRL-sensitive shift is indicated with an
arrow. This is a representative experiment independently performed
three times. B: Cytosolic and nuclear extracts were prepared from
3T3-L1 adipocytes treated with PRL for 15 min. For supershift analysis,
10 g protein was preincubated with 4 g indicated antibody and then
incubated with 50,000 cpm/ml indicated 32P-labeled probe of the 389
to 378 site in the murine PDK4 promoter. The protein-DNA com-
plexes were resolved by EMSA. This is a representative experiment
independently performed two times.
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the levels of PDK4 protein were the greatest after an 8- to
10-h treatment. However, in all of our experiments, there
was no significant effect observed after a 22-h PRL treat-
ment. The efficacy of the PRL treatment was demonstrated
by showing the activation of STAT5 and ERK 1 and 2
(active MAPK).
Because PRL induced PDK4 proteins levels, we hypoth-
esized that glucose uptake might be regulated under these
conditions. The results in Fig. 8 demonstrate that a 10-min
treatment with insulin results in a fivefold increase in
glucose uptake in fully differentiated 3T3-L1 adipocytes.
Also, a 6-h treatment with PRL resulted in a substantial
decrease (2.5-fold) in insulin-stimulated glucose uptake.
The induction of PDK4 protein under these conditions was
confirmed by Western blot analysis (data not shown).
DISCUSSION
The novel findings in this study include data demonstrat-
ing that PDK4 levels are induced in adipocytes after
stimulation with two STAT5-activating hormones, the
identification of a hormone-responsive region in the mu-
rine PDK4 promoter, and the characterization of a STAT5
binding site in this region. These results strongly suggest
that STAT5A directly activates the expression of PDK4 in
adipocytes. Moreover, our data indicate that PRL and
STAT5A could induce conditions of insulin resistance by
inducing PDK4 expression and attenuating insulin-stimu-
lated glucose uptake.
Although GH is a well-known modulator of metabolism
and is a known effector of insulin action (rev. in 2 and 33),
the role of PRL in these processes is less understood. PRL
is primarily a pituitary secreted hormone, yet in humans,
PRL is also produced and secreted from additional tissues,
such as human glandular and adipose breast tissues (34)
and human decidua (35), and is a circulating hormone
(rev. in 36). The presence of PRL receptors in almost all
organs, including adipocytes (3), contributes to the diverse
roles of PRL. Recently, a novel human adipocyte cell line,
LS14, has been developed that produces and responds to
PRL (37). In morbidly obese patients, the amount of PRL
secreted from subcutaneous adipose tissue is much less
than in lean patients, but, surprisingly, there are no
apparent differences in PRL secretion between men and
women (rev. in 36).
Studies have also implicated PRL as a contributor to
insulin resistance. One study conducted in lean preg-
nant women demonstrated that PRL could cause insulin
resistance in adipocytes by suppressing adiponectin
production and secretion (38). This mechanism is plau-
FIG. 6. PRL and GH induce the activity of the murine PDK4 promoter in
3T3-L1 cells via a STAT5 binding site. Proliferating 3T3-L1 cells were
transiently transfected with murine PDK4 promoter (949 to 24)/
luciferase constructs (wild type or mutant) and the TK/renilla vector
to control for transfection efficiency. After 48 h of transfection, cells
were stimulated with 0.5 nmol/l PRL or 0.5 nmol/l porcine GH for 2 h.
Relative light units (RLU) were calculated by dividing firefly luciferase
activity by renilla luciferase activity. Results are shown as SD. For
each experiment, three plates of cells were used for each particular
condition. In addition, each experiment was performed in triplicate on
three independent batches of cells with similar results.
FIG. 7. PRL induces the expression of PDK4 protein in 3T3-L1 adipo-
cytes in a time-dependent manner. Fully differentiated 3T3-L1 adipo-
cytes were serum deprived overnight and then exposed to 20 nmol/l
PRL for the times indicated. One hundred micrograms protein from
whole-cell extracts was loaded into the gel for each sample. The
samples were subjected to SDS-PAGE and then were transferred to
nitrocellulose for immunoblot analysis. PDK4 polyclonal antibodies
were purchased from Abgent and used at a dilution of 1:200. STAT5A
polyclonal antibodies were purchased from Santa Cruz and used at a
1:500 dilution. A STAT5 pY694/699 polyclonal antibody was purchased
from Upstate Cell Signaling and used at 1:500 dilution. Active MAPK
polyclonal antibodies was purchased from Promega and used at a
1:5,000 dilution. This is a representative experiment independently
performed four times.
FIG. 8. The effects of PRL on insulin-stimulated glucose uptake in
3T3-L1 adipocytes. Serum-deprived, fully differentiated 3T3-L1 adipo-
cytes were untreated or incubated with 0.5 nmol/l PRL for 6 h. Cells
were then exposed to 50 nmol/l insulin or saline control for 10 min.
Glucose uptake was measured as described in RESEARCH DESIGN AND
METHODS. Values shown represent the means  SE (light bars, saline
control; dark bars, insulin treatment) of triplicate determinations
from four independent experiments.
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sible, because low levels of adiponectin can be associ-
ated with obesity and insulin resistance. Although the
cross-talk between PRL and leptin action is not well
understood, PRL has been shown to suppress insulin-
induced leptin secretion in cultured adipocytes (39).
PRL also decreases insulin-stimulated glucose uptake in
pregnant rat adipose tissue (40). Likewise, severe hy-
perprolactinemia has been shown to induce an insulin-
resistant state by decreasing insulin binding in human
subjects (41). Our data present another plausible mech-
anism by which PRL may cause insulin resistance in
adipocytes by modulating PDK4 levels.
Previous studies support similar or overlapping func-
tions for PRL and GH in mammary gland metabolism (42).
Our studies revealed that sheep PRL and porcine GH
behaved similarly to modulate PDK4 levels in murine
adipocytes. As is commonly known for PRL action, we did
observe a bell-shaped curve rather than linear dose-depen-
dence relationship, and higher doses of the hormone were
inhibitory. Interestingly, human GH had no substantial
effects on PDK4, despite its ability to weakly activate
STAT5A and strongly activate ERK 1 and 2. In multiple
independent experiments, we demonstrated the induction
of PDK4 specifically by sheep PRL and porcine GH but not
by human GH in 3T3-L1 adipocytes. These data are intrigu-
ing because human GH did result in some activation of
STAT5A but did not induce PDK4 levels. A BLAST analysis
revealed that human GH and mouse GH have a 69.7%
similarity (58.3% identity). However, porcine GH and mu-
rine GH have a 94.4% similarity (89.8% identity). Hence, we
hypothesize that the human GH does not engage the
murine receptor normally because of the substantial dif-
ference in homology. Alternatively, the activation of
STAT5 by sheep PRL and porcine GH may include an
additional factor(s) that participates in the induction of
PDK4 expression, and this factor is not similarly modu-
lated by human GH signaling in murine adipocytes.
Although it has been shown that insulin has the ability to
suppress PDK4 expression in various other tissues (23–
25), our studies demonstrate that insulin has the ability to
suppress the PRL- and GH-induced PDK4 expression in
adipocytes. Because the basal levels of PDK4 are low in
adipocytes, we did not observe a strong repression of
PDK4 mRNA after insulin treatment alone (Fig. 2). Our
studies provide evidence to support antagonistic cross-
talk between PRL or GH and insulin, as well as the
possible role of PRL in insulin resistance in adipose tissue.
In addition, our results indicate that a 6-h PRL treatment
results in an inhibition of insulin-sensitive glucose uptake.
This data are complemented by studies showing that
reduced PDK4 expression is associated with increased
insulin sensitivity (26). In summary, the presence of PDK4
protein in adipocytes correlates with an attenuation of
insulin-sensitive glucose uptake and likely plays a role in
the ability of PRL to induce insulin resistance.
Studies have shown that other transcription factors,
such as FOXO, also bind to the PDK4 promoter and induce
PDK4 expression in response to starvation in the skeletal
muscle of mice (43). Glucocorticoids, which are impli-
cated in insulin resistance, also increase the expression of
PDK4, and insulin antagonizes these effects (25). Addi-
tional studies show that insulin suppresses the PDK4
induction mediated by glucocorticoids by inactivation of
FOXO transcription factors, which are required for full
transcriptional activation of the PDK4 gene by glucocorti-
coids (44). The transcriptional coactivator peroxisome
proliferator–activated  coactivator (PGC)1 has also
been shown to induce the expression of PDK4 in primary
rat hepatocytes and ventricular myocytes (45). In C2C12
myoblasts, PGC1 induces PDK4 expression in a manner
that is dependent on ERR (46). Hence, in muscle, the
modulation of PDK4 can be influenced by FOXO transcrip-
tion factors and PGC1. Our studies demonstrate a novel
induction of PDK4 in adipocytes that is mediated by a
STAT5A binding site in the mPDK4 promoter. Other stud-
ies from our laboratory have shown that adipocyte
STAT5A can inhibit the expression of FAS (12) and bind to
the promoter of the acyl Co-A oxidase (AOX) gene, which
correlates with an increase in AOX expression (47).
Hence, the role of STAT5A in mature adipocytes appears
to be one that attenuates lipid accumulation and favors
lipid oxidation. Interestingly, our studies on PDK4 also
suggest that STAT5A may contribute to energy homeosta-
sis by decreasing glucose oxidation and increasing insulin
resistance in adipocytes. The differential capabilities of
STAT5A are apparent from several studies that demon-
strate that in various preadipocytes or nonprecursor cells,
STAT5A can promote lipid accumulation and adipogenesis
(7–9). Although the mechanisms that account for the
ability of STAT5A to have lipogenic or lipolytic effects
have not been clearly defined, collectively, these studies
indicate that STAT5A is likely an important contributor to
maintenance of energy balance, particularly in response to
hormones.
Because PDK inhibitors have been shown to be effective
potential therapeutics in improving glycemic control and
type 2 diabetes (48), these kinases warrant more in-depth
analysis. In particular, PDK4 proves to be an object of
necessary consideration because it is expressed in sub-
stantial amounts in skeletal muscle and adipose tissue. In
summary, we have observed that PRL and GH can induce
the expression of PDK4 in adipocytes and positively
regulate the murine PDK4 promoter. Our identification of
a STAT5 binding site in the promoter of PDK4 character-
izes a novel mechanism of regulating its expression. In
summary, we hypothesize that the regulation of PDK4 by
PRL and GH via STAT5A is likely an important contribu-
tion to the maintenance of energy homeostasis.
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